Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Condition(s):Colorectal Cancer Stage IV; No Evidence of Disease StateLast Updated:May 17, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Colorectal Cancer Stage IV; No Evidence of Disease StateLast Updated:May 17, 2023Recruiting
Condition(s):Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v7Last Updated:July 19, 2022Active, not recruiting
Condition(s):Metastatic Colorectal Cancer; No Evidence of Disease Status; ctDNA MonitoringLast Updated:December 2, 2022Recruiting
Condition(s):Breast CancerLast Updated:June 19, 2013Completed
Condition(s):Healthy, no Evidence of DiseaseLast Updated:June 23, 2014Completed
Condition(s):Healthy, no Evidence of DiseaseLast Updated:August 26, 2013Unknown status
Condition(s):Healthy, No Evidence of DiseaseLast Updated:April 7, 2017Completed
Condition(s):Squamous Cell CarcinomaLast Updated:February 21, 2024Recruiting
Condition(s):Metastatic Colorectal Cancer,NEDLast Updated:December 12, 2023Recruiting
Condition(s):Malignant MelanomaLast Updated:December 13, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.